Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 20 January 2016 | By Zachary Brennan
As medical devices are sterilized with novel and sometimes risky new methods and chemical combinations, the US Food and Drug Administration (FDA) announced Wednesday that it will begin inspecting companies' manufacturing facilities before clearing their 510(k) applications.
The shift in FDA’s thinking comes as the agency says in Wednesday’s final guidance, issued more than seven years after the draft document was released, that it’s received “an increasing number of 510(k)s for devices labeled as sterile that use sterilization methods other than the traditionally used methods of steam, dry heat, ethylene oxide (EO), and radiation.”
And although the agency has experience with other sterilization methods -- such as with hydrogen peroxide, ozone and flexible bag systems, and now considers those to be established methods -- there “may be alterations to the more recently developed methods, as well as original, innovative sterilization technologies, which are being developed and proposed for use in the manufacture of class I and class II devices. FDA considers these to be novel methods.”
FDA considers there to be two categories of sterilization methods for medical devices: established and novel.
On the established front, these are methods with a history of safe and effective use as demonstrated through literature, clearances of 510(k)s or approvals of premarket approval (PMA) applications, and satisfactory quality system inspections.
“For established methods such as dry heat, EO, steam, and radiation, there are voluntary consensus standards for development, validation, and routine control that are recognized by FDA,” the agency says.
Examples of established sterilization methods include: dry heat, EO with devices in a fixed, rigid chamber, moist heat or steam and radiation (e.g., gamma, electron beam).
In cases where FDA has previously evaluated sterilization development and validation data for specific sterilizers and determined the methods to be adequate, the agency says other established methods include: hydrogen peroxide, ozone and flexible bag systems (e.g., EO in a flexible bag system, diffusion method, injection method).
Methods FDA has not reviewed and determined to effectively sterilize a device for its intended use are considered novel and can include using chemical(s) that have not been previously approved by FDA as a chemical sterilant or that have not been identified in the scientific literature as a chemical sterilant.
And the agency notes that even if a sterilization method uses a combination of chemicals made up of individual chemicals previously approved independently, FDA would consider such a method as novel.
Examples of novel sterilization methods include: vaporized peracetic acid; high-intensity light or pulse light; microwave radiation; sound waves; and ultraviolet light.
The guidance goes on to outline what sponsors should be sure to include in their 510(k) submission, as well this additional information for all novel sterilization methods:
The agency also makes clear to note what should be excluded from this guidance, including: sterilizers that are themselves medical devices subject to 510(k); processes that rely on microbial exclusion, rather than microbial inactivation; processes intended to sterilize medical devices that incorporate materials of animal origin (i.e., human or animal tissues); processes that incorporate the use of liquid chemical sterilants; and processes intended to be used by reprocessors of single-use devices.
The guidance also provides details about the pyrogenicity information that FDA recommends sponsors include in a 510(k) submission.
On Thursday 11 February, FDA will hold a webinar to help
manufacturers understand the information provided in this final guidance
document. The agency says it will respond to
Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile
Tags: 510(k) submission, medical device FDA, device sterilization, sterilants
Regulatory Focus newsletters
All the biggest regulatory news and happenings.